Summary.
This study examined the potential of L-Deprenyl, a selective monoamine oxidase-B (MAO-B) inhibitor, for the treatment of neuroleptic-induced parkinsonism (NIP). Thirty-one consecutive schizophrenic or schizophreniform patients were treated with haloperidol in a flexible dose design. Nineteen of them developed NIP and were administered adjunctive L-Deprenyl 10 mg/d for six weeks in an open fixed-dose design. One patient had to be withdrawn from the study because of exacerbation of the NIP. Severity of NIP was mild to moderate throughout the whole study period in all other cases. Five patients were considered to require biperiden 2–4 mg/d in addition to L-Deprenyl after two weeks of treatment, although they did not differ from the other 13 patients in any of the variables studied. A significant improvement in NIP was found in both groups of patients, with no psychotic exacerbation or a change in the dosage of haloperidol. These findings suggest that selective MAO-B inhibitors may be effective in some patients with mild to moderate NIP.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received September 1, 1997; accepted March 5, 1999
Rights and permissions
About this article
Cite this article
Rapoport, A., Stein, D., Schwartz, M. et al. A trial of L-Deprenyl for the treatment of neuroleptic-induced parkinsonism. J Neural Transm 106, 911–918 (1999). https://doi.org/10.1007/s007020050210
Issue Date:
DOI: https://doi.org/10.1007/s007020050210